CIK 0001640266 · Accelerated filer<br>Smaller reporting company
Voyager Therapeutics, Inc.
Sign in to watch- Ticker
- VYGR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-259-5340
- Business address
- 75 HAYDEN AVENUE, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-05 | Higgins Michael J Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-06-05 | GERAGHTY JAMES A Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-06-05 | Colon Grace Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2024-04-02 | Swartz Robin Chief Operating Officer | Sale | −1,357 | $9.88 | $13K | 117,004 |
| 2024-04-02 | Sandrock Alfred President and CEO | Sale | −12,115 | $9.86 | $119K | 322,839 |
| 2024-04-01 | Ferguson Toby Chief Medical Officer | Grant or award | +105,000 | 105,000 | ||
| 2024-03-25 | Ferguson Toby Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +210,000 | 210,000 | ||
| 2024-02-21 | Swartz Robin Chief Operating Officer | Sale | −3,966 | $7.45 | $30K | 118,361 |
| 2024-02-21 | Sandrock Alfred President and CEO | Sale | −13,033 | $7.46 | $97K | 334,954 |
| 2024-02-21 | PFREUNDSCHUH PETER P. Chief Financial Officer | Sale | −3,764 | $7.46 | $28K | 175,669 |
| 2024-02-21 | Carter Todd Alfred Chief Scientific Officer | Sale | −3,365 | $7.47 | $25K | 87,627 |
| 2024-02-20 | Carter Todd Alfred Chief Scientific Officer | Sale | −602 | $7.68 | $5K | 90,992 |
| 2024-02-09 | Fahey Sandell Jacquelyn Chief Legal Officer | Grant or award | +31,000 | 92,000 | ||
| 2024-02-09 | Fahey Sandell Jacquelyn Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +62,000 | 62,000 | ||
| 2024-02-09 | Carter Todd Alfred Chief Scientific Officer | Grant or award | +38,500 | 91,594 | ||
| 2024-02-09 | Carter Todd Alfred Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +77,000 | 77,000 | ||
| 2024-02-09 | Swartz Robin Chief Operating Officer | Grant or award | +50,000 | 122,327 | ||
| 2024-02-09 | Swartz Robin Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-02-09 | Sandrock Alfred President and CEO | Grant or award | +130,000 | 347,987 | ||
| 2024-02-09 | Sandrock Alfred President and CEO | Grant or award · Stock Option (Right to Buy) | +260,000 | 260,000 |
Page 5 of 7 · 130 trades